Blood–brain barrier (BBB)–crossing antibody therapeutics, which utilize brain transport mechanisms, such TfR1 and CD98, are generating a lot of excitement in CNS drug discovery. A key challenge is quantitatively measuring where these therapeutics actually distribute within the brain – vasculature vs parenchyma. Translucence Biosystems provides whole-brain tissue clearing, light-sheet imaging, and quantitative analysis to visualize and measure antibody penetration and cellular localization across the entire brain in preclinical models. With spatial maps of therapeutic distribution, Translucence helps drug developers evaluate BBB transport strategies, optimize dosing and molecular design, and de-risk CNS biologics programs earlier in development.